公开(公告)号：US20180273640A1

公开(公告)日：2018-09-27

申请号：US15990561

申请日：2018-05-25

申请人： Celgene Corporation

发明人： Bitao Liang ,  Stewart Abbot ,  Wei Liu

IPC分类号： C07K16/40 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC分类号： C07K16/40 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00

摘要： Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.

公开(公告)号：US11130820B2

公开(公告)日：2021-09-28

申请号：US16175747

申请日：2018-10-30

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Bitao Liang ,  Tianjian Li

IPC分类号： C07K16/30 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

摘要： Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.

公开(公告)号：US20190119399A1

公开(公告)日：2019-04-25

申请号：US16175747

申请日：2018-10-30

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Bitao Liang ,  Tianjian Li

IPC分类号： C07K16/30 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

摘要： Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.

公开(公告)号：US10967005B2

公开(公告)日：2021-04-06

申请号：US16276581

申请日：2019-02-14

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Tianjian Li ,  Bitao Liang

IPC分类号： A61K38/17 ,  A61K39/00 ,  C07K5/10 ,  A61K39/395 ,  A61K35/17 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C12N9/64

摘要： Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

公开(公告)号：US10150816B2

公开(公告)日：2018-12-11

申请号：US14653650

申请日：2013-12-19

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Bitao Liang ,  Tianjian Li

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/705 ,  C07K14/725

摘要： Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.

公开(公告)号：US11834675B2

公开(公告)日：2023-12-05

申请号：US16067536

申请日：2016-12-29

申请人： CELGENE CORPORATION

发明人： Bitao Liang ,  Xiaohua Lu ,  Wei Liu ,  Kathy E. Karasciewicz-Mendez ,  Christopher Wiwi ,  Kruti Shah

IPC分类号： C12N5/0783 ,  A61K39/00 ,  A61K35/17 ,  C07K16/28

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  C07K16/2818 ,  C07K16/2827 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2315

摘要： Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation. Also provided herein are methods of using said cytotoxic T lymphocytes, for example, to treat cancer and/or viral infection.

公开(公告)号：US11629335B2

公开(公告)日：2023-04-18

申请号：US17200745

申请日：2021-03-12

申请人： CELGENE CORPORATION

发明人： Bitao Liang ,  Wei Liu

IPC分类号： C12N7/00 ,  A61K39/00 ,  C12N5/0783 ,  C12N15/86 ,  C12N15/87

摘要： Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.

公开(公告)号：US20190175652A1

公开(公告)日：2019-06-13

申请号：US16276581

申请日：2019-02-14

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Tianjian Li ,  Bitao Liang

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K16/28 ,  A61K38/17 ,  C07K14/725 ,  C12N5/0783 ,  A61K39/395 ,  C12N9/64

摘要： Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

公开(公告)号：US11806365B2

公开(公告)日：2023-11-07

申请号：US17193865

申请日：2021-03-05

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Tianjian Li ,  Bitao Liang

IPC分类号： C12N5/10 ,  A61K35/17 ,  A61K38/17 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C12N9/64 ,  A61K39/395 ,  A61K39/00

CPC分类号： A61K35/17 ,  A61K38/1709 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2887 ,  C12N5/0636 ,  C12N9/6475 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70 ,  C12N2510/00

摘要： Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

公开(公告)号：US20210299175A1

公开(公告)日：2021-09-30

申请号：US17193865

申请日：2021-03-05

申请人： CELGENE CORPORATION

发明人： Stewart Abbot ,  Tianjian Li ,  Bitao Liang

IPC分类号： A61K35/17 ,  A61K38/17 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C12N9/64 ,  A61K39/395

摘要： Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.